600535 天士力
已收盘 10-23 15:00:00
资讯
新帖
简况
股市必读：天士力三季报 - 第三季度单季净利润同比增长0.10%
证券之星 · 03:43
股市必读：天士力三季报 - 第三季度单季净利润同比增长0.10%
天士力(600535.SH)发布前三季度业绩，归母净利润11.03亿元，同比增长12.01%
智通财经 · 10-23 19:12
天士力(600535.SH)发布前三季度业绩，归母净利润11.03亿元，同比增长12.01%
华润医药：天士力医药前三季度净利润10.87亿元 同比增加9.52%
同花顺 · 10-23 18:09
华润医药：天士力医药前三季度净利润10.87亿元 同比增加9.52%
天士力（600535）10月19日主力资金净买入136.33万元
证券之星 · 10-20
天士力（600535）10月19日主力资金净买入136.33万元
股市必读：天士力新发布《天士力关于子公司获得药品注册证书的公告》
证券之星 · 10-19
股市必读：天士力新发布《天士力关于子公司获得药品注册证书的公告》
XD天士力（600535）10月15日主力资金净卖出952.25万元
证券之星 · 10-16
XD天士力（600535）10月15日主力资金净卖出952.25万元
股市必读：天士力新发布《天士力关于获得药物临床试验批准通知书的公告》
证券之星 · 10-16
股市必读：天士力新发布《天士力关于获得药物临床试验批准通知书的公告》
天士力(600535.SH)子公司获得注射用雷替曲塞药品注册证书
智通财经 · 10-15
天士力(600535.SH)子公司获得注射用雷替曲塞药品注册证书
天士力（600535）披露获得药物临床试验批准通知书的公告，10月14日股价上涨2.22%
证券之星 · 10-14
天士力（600535）披露获得药物临床试验批准通知书的公告，10月14日股价上涨2.22%
天士力(600535.SH)：TDX105颗粒获得药物临床试验批准
智通财经 · 10-14
天士力(600535.SH)：TDX105颗粒获得药物临床试验批准
天士力（600535）披露选举职工董事公告，10月13日股价下跌1.76%
证券之星 · 10-13
天士力（600535）披露选举职工董事公告，10月13日股价下跌1.76%
股市必读：天士力新发布《天士力2026年半年度权益分派实施公告》
证券之星 · 10-12
股市必读：天士力新发布《天士力2026年半年度权益分派实施公告》
天士力(600535.SH)子公司注射用吲哚菁绿获得药品注册证书
智通财经 · 10-09
天士力(600535.SH)子公司注射用吲哚菁绿获得药品注册证书
股市必读：天士力新发布《天士力2026年半年度权益分派实施公告》
证券之星 · 10-09
股市必读：天士力新发布《天士力2026年半年度权益分派实施公告》
天士力（600535）9月28日主力资金净买入116.00万元
证券之星 · 09-29
天士力（600535）9月28日主力资金净买入116.00万元
股市必读：天士力新发布《天士力第九届董事会第25次会议决议公告》
证券之星 · 09-28
股市必读：天士力新发布《天士力第九届董事会第25次会议决议公告》
天士力（600535）披露董事会审计委员会委员调整公告，9月24日股价下跌1.51%
证券之星 · 09-24
天士力（600535）披露董事会审计委员会委员调整公告，9月24日股价下跌1.51%
天士力：公司将切实落实“十五五”战略规划中的关键举措
证券之星 · 09-21
天士力：公司将切实落实“十五五”战略规划中的关键举措
天士力：公司拥有在研创新药33项
证券之星 · 09-21
天士力：公司拥有在研创新药33项
研报掘金丨东方证券：维持天士力“买入”评级，核心品种稳健增长，创新管线蓄势待发
格隆汇 · 09-15
研报掘金丨东方证券：维持天士力“买入”评级，核心品种稳健增长，创新管线蓄势待发
加载更多
公司概况
公司名称：
天士力医药集团股份有限公司
所属行业：
医药制造业
上市日期：
2002-08-23
主营业务：
天士力医药集团股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是复方丹参滴丸、养血清脑丸（颗粒）、芪参益气滴丸、水林佳（水飞蓟宾胶囊）、注射用重组人尿激酶原（普佑克）、芍麻止痉颗粒。公司连续多年荣获“中国医药工业百强”、“中国医药创新企业100强”、“中国药品研发综合实力50强”、“中国中药研发实力10强”等称号。
发行价格：
14.70
{"stockData":{"symbol":"600535","market":"SH","secType":"STK","nameCN":"天士力","latestPrice":13.78,"timestamp":1792738800000,"preClose":13.72,"halted":0,"volume":12431619,"delay":0,"changeRate":0.0044,"floatShares":1494000000,"shares":1494000000,"eps":0.8188,"marketStatus":"已收盘","change":0.06,"latestTime":"10-23 15:00:00","open":13.72,"high":13.84,"low":13.58,"amount":171000000,"amplitude":0.019,"askPrice":13.78,"askSize":126,"bidPrice":13.77,"bidSize":267,"shortable":0,"etf":0,"ttmEps":0.8188,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792978200000},"marketStatusCode":5,"adr":0,"adjPreClose":13.72,"symbolType":"stock","openAndCloseTimeList":[[1792719000000,1792726200000],[1792731600000,1792738800000]],"highLimit":15.09,"lowLimit":12.35,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1493950005,"isCdr":false,"pbRate":1.57,"roa":"--","peRate":16.829507,"roe":"6.98%","epsLYR":0.74,"committee":-0.13882,"marketValue":20587000000,"turnoverRate":0.0083,"status":0,"floatMarketCap":20587000000},"requestUrl":"/m/hq/s/600535","defaultTab":"news","newsList":[{"id":"2678042136","title":"股市必读：天士力三季报 - 第三季度单季净利润同比增长0.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678042136","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678042136?lang=zh_cn&edition=full","pubTime":"2026-10-26 03:43","pubTimestamp":1792957389,"startTime":"0","endTime":"0","summary":"业绩披露要点：2026年前三季度归母净利润11.03亿元，同比上升12.01%；扣非净利润11.19亿元，同比大幅上升34.96%。2026年第三季度单季度主营收入18.73亿元，同比下降7.41%；归母净利润2.1亿元，同比上升0.1%；扣非净利润2.49亿元，同比上升31.45%；负债率13.42%，毛利率68.5%。公司公告汇总天士力2026年第三季度报告本报告期营业收入18.73亿元，同比下降7.41%；归母净利润2.10亿元，同比增长0.10%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600000947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677926076","title":"天士力(600535.SH)发布前三季度业绩，归母净利润11.03亿元，同比增长12.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677926076","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677926076?lang=zh_cn&edition=full","pubTime":"2026-10-23 19:12","pubTimestamp":1792753957,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天士力(600535.SH)披露2026年第三季度报告，前三季度公司实现营业收入60.74亿元，同比下降3.76%;归母净利润11.03亿元，同比增长12.01%;扣非净利润11.19亿元，同比增长34.96%;基本每股收益0.74元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1511734.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677923914","title":"华润医药：天士力医药前三季度净利润10.87亿元 同比增加9.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677923914","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677923914?lang=zh_cn&edition=full","pubTime":"2026-10-23 18:09","pubTimestamp":1792750140,"startTime":"0","endTime":"0","summary":"华润医药(03320)发布公告，附属天士力医药集团股份有限公司(天士力医药)截至2026年9月30日止9个月取得营业总收入人民币60.74亿元，同比减少3.76%;净利润10.87亿元，同比增加9.52%。 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261023/c681036461.shtml","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261023/c681036461.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159938","600535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676869637","title":"天士力（600535）10月19日主力资金净买入136.33万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2676869637","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676869637?lang=zh_cn&edition=full","pubTime":"2026-10-20 08:22","pubTimestamp":1792455769,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月19日收盘，天士力报收于14.39元，上涨2.49%，换手率1.05%，成交量15.66万手，成交额2.24亿元。近5日资金流向一览见下表：天士力融资融券信息显示，融资方面，当日融资买入1987.45万元，融资偿还2889.85万元，融资净偿还902.4万元。融券方面，融券卖出2600.0股，融券偿还9400.0股，融券余量60.16万股，融券余额865.7万元。天士力主营业务：药品的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000005144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","BK0012","600535","BK0188","BK0028","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676578256","title":"股市必读：天士力新发布《天士力关于子公司获得药品注册证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2676578256","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676578256?lang=zh_cn&edition=full","pubTime":"2026-10-19 02:00","pubTimestamp":1792346438,"startTime":"0","endTime":"0","summary":"公司公告汇总：子公司江苏天士力帝益药业获注射用雷替曲塞《药品注册证书》，该药为化学药品3类、视同通过仿制药一致性评价，2025年国内销售金额达4.18亿元。公司公告汇总天士力关于子公司获得药品注册证书的公告天士力医药集团股份有限公司全资子公司江苏天士力帝益药业有限公司收到国家药品监督管理局核准签发的注射用雷替曲塞《药品注册证书》。截至目前，国内共有6家厂家获得该药品注册证书。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900000618.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0183","BK0196","BK0012","BK0028","600535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675559570","title":"XD天士力（600535）10月15日主力资金净卖出952.25万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675559570","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675559570?lang=zh_cn&edition=full","pubTime":"2026-10-16 08:16","pubTimestamp":1792109779,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月15日收盘，XD天士力报收于14.09元，上涨0.36%，换手率1.03%，成交量15.41万手，成交额2.18亿元。10月15日的资金流向数据方面，主力资金净流出952.25万元，占总成交额4.38%，游资资金净流出38.68万元，占总成交额0.18%，散户资金净流入990.93万元，占总成交额4.55%。近5日资金流向一览见下表：天士力融资融券信息显示，融资方面，当日融资买入1321.19万元，融资偿还2668.17万元，融资净偿还1346.98万元。XD天士力主营业务：药品的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600007148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0183","BK0239","600535","BK0028","BK0188","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675898534","title":"股市必读：天士力新发布《天士力关于获得药物临床试验批准通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675898534","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675898534?lang=zh_cn&edition=full","pubTime":"2026-10-16 01:47","pubTimestamp":1792086431,"startTime":"0","endTime":"0","summary":"公司公告汇总：天士力收到《药物临床试验批准通知书》，TDX105颗粒获批开展Ⅱ、Ⅲ期临床试验，系中药创新药1.1类。该药尚需完成临床试验并经审评审批后方可上市。天士力关于子公司获得药品注册证书的公告天士力医药集团股份有限公司全资子公司江苏天士力帝益药业有限公司收到国家药品监督管理局核准签发的注射用雷替曲塞《药品注册证书》。截至目前，国内共有6家厂家获得该药品注册证书。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600002190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0183","BK0188","BK0012","600535","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675585854","title":"天士力(600535.SH)子公司获得注射用雷替曲塞药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2675585854","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675585854?lang=zh_cn&edition=full","pubTime":"2026-10-15 18:21","pubTimestamp":1792059702,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天士力(600535.SH)发布公告，近日，公司全资子公司江苏天士力帝益药业有限公司(简称“江苏帝益”)收到国家药品监督管理局核准签发的注射用雷替曲塞《药品注册证书》。公司药品注射用雷替曲塞的适应症为在患者无法接受联合化疗时，本品可单药用于治疗不适合5-Fu/亚叶酸钙的晚期结直肠癌患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1507799.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"天士力(600535.SH)子公司获得注射用雷替曲塞药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0239","BK0196","BK0028","600535","BK0183","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675328309","title":"天士力（600535）披露获得药物临床试验批准通知书的公告，10月14日股价上涨2.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675328309","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675328309?lang=zh_cn&edition=full","pubTime":"2026-10-14 22:15","pubTimestamp":1791987321,"startTime":"0","endTime":"0","summary":"截至2026年10月14日收盘，天士力报收于14.28元，较前一交易日上涨2.22%，最新总市值为213.34亿元。近日，天士力医药集团股份有限公司披露《关于获得药物临床试验批准通知书的公告》。公司收到国家药监局核准签发的《药物临床试验批准通知书》，同意TDX105颗粒开展用于肿瘤化疗/靶向治疗引起的相关皮肤不良反应湿热瘀阻证的Ⅱ、Ⅲ期临床试验。截至公告日，累计研发投入1,262.67万元。该药尚需完成临床试验并经审评审批后方可上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400039820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","BK0012","600535","BK0188","BK0028","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675667311","title":"天士力(600535.SH)：TDX105颗粒获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2675667311","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675667311?lang=zh_cn&edition=full","pubTime":"2026-10-14 15:55","pubTimestamp":1791964551,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天士力(600535.SH)发布公告，近日，公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于TDX105颗粒的《药物临床试验批准通知书》。TDX105颗粒是基于中国医学科学院肿瘤医院(国家癌症中心)临床经验方研制的中药1.1类新药，本品处方组成、用法用量均与临床经验方临床应用保持一致，此临床经验方已在临床使用多年，临床观察显示其对肿瘤治疗药物相关皮肤不良反应引起的瘙痒、疼痛等皮肤损伤有明显缓解作用，具有较好的疗效及安全性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1506991.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0012","MDTX","BK0196","BK0028","BMED","BK0183","PSYK","BK0239","IBBJ","IBBQ","600535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675337086","title":"天士力（600535）披露选举职工董事公告，10月13日股价下跌1.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675337086","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675337086?lang=zh_cn&edition=full","pubTime":"2026-10-13 17:33","pubTimestamp":1791884001,"startTime":"0","endTime":"0","summary":"截至2026年10月13日收盘，天士力报收于13.97元，较前一交易日下跌1.76%，最新总市值为208.7亿元。天士力医药集团股份有限公司于2026年10月10日召开第一届职工代表大会第五次会议，选举王皓蔚先生为公司第九届董事会职工董事，任期自选举产生之日起至本届董事会任期届满。王皓蔚先生符合相关法律法规及公司章程规定的任职资格。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300029273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0196","600535","BK0188","BK0012","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674684302","title":"股市必读：天士力新发布《天士力2026年半年度权益分派实施公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674684302","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674684302?lang=zh_cn&edition=full","pubTime":"2026-10-12 01:41","pubTimestamp":1791740467,"startTime":"0","endTime":"0","summary":"当日关注点交易信息汇总：10月9日主力资金净流出1577.21万元，占总成交额6.75%； 公司公告汇总：天士力将于10月15日发放2026年半年度现金红利，每股0.24元（含税），总额3.59亿元； 公司公告汇总：子公司获注射用吲哚菁绿《药品注册证书》，视同通过仿制药一致性评价，累计研发投入416.17万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200000540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600535","BK0196","BK0028","BK0239","BK0183","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674704832","title":"天士力(600535.SH)子公司注射用吲哚菁绿获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2674704832","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674704832?lang=zh_cn&edition=full","pubTime":"2026-10-09 16:52","pubTimestamp":1791535946,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天士力(600535.SH)发布公告，近日，公司全资子公司天津天士力之骄药业有限公司收到国家药品监督管理局核准签发的注射用吲哚菁绿《药品注册证书》。注射用吲哚菁绿临床上用于诊断肝硬化、肝纤维化、韧性肝炎、职业和药物中毒性肝病等各种肝脏疾病，了解肝脏的损害程度及其储备功能;也可用于脉络膜血管造影，确定脉络膜疾患的位置。该药品按化学药品3类注册申报，视同通过仿制药一致性评价。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505207.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","600535","BK0196","BK0028","BK0239","BK0183","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674442004","title":"股市必读：天士力新发布《天士力2026年半年度权益分派实施公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674442004","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674442004?lang=zh_cn&edition=full","pubTime":"2026-10-09 02:08","pubTimestamp":1791482892,"startTime":"0","endTime":"0","summary":"当日关注点交易信息汇总：10月8日主力资金净流出444.36万元，占总成交额2.11%； 公司公告汇总：天士力将于2026年10月15日发放2026年半年度现金红利，每股0.24元（含税），总额3.585亿元。公司公告汇总天士力2026年半年度权益分派实施公告天士力医药集团股份有限公司2026年半年度权益分派实施公告：每股派发现金红利0.24元（含税），股权登记日为2026年10月14日，除权（息）日和现金红利发放日均为2026年10月15日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900002122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","600535","BK0012","BK0028","BK0183","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671218266","title":"天士力（600535）9月28日主力资金净买入116.00万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671218266","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671218266?lang=zh_cn&edition=full","pubTime":"2026-09-29 08:24","pubTimestamp":1790641457,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月28日收盘，天士力报收于13.8元，上涨0.88%，换手率0.73%，成交量10.93万手，成交额1.5亿元。近5日资金流向一览见下表：天士力融资融券信息显示，融资方面，当日融资买入1974.36万元，融资偿还1557.39万元，融资净买入416.97万元，连续3日净买入累计1035.25万元。天士力主营业务：药品的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900007135.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600535","BK0012","BK0239","BK0196","BK0183","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670090094","title":"股市必读：天士力新发布《天士力第九届董事会第25次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2670090094","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670090094?lang=zh_cn&edition=full","pubTime":"2026-09-28 02:48","pubTimestamp":1790534894,"startTime":"0","endTime":"0","summary":"公司公告汇总天士力第九届董事会第25次会议决议公告天士力医药集团股份有限公司于2026年9月24日召开第九届董事会第25次会议，审议通过关于调整公司董事会审计委员会委员的议案。调整后审计委员会由王爱俭女士任主任委员，王亮先生、段亚林先生为成员，任期至第九届董事会任期届满。会议应到董事14人，实到14人，表决结果为同意14票，反对0票，弃权0票。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800001390.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600535","BK0196","BK0183","BK0028","BK0239","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669525499","title":"天士力（600535）披露董事会审计委员会委员调整公告，9月24日股价下跌1.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669525499","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669525499?lang=zh_cn&edition=full","pubTime":"2026-09-24 22:23","pubTimestamp":1790259795,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘，天士力报收于13.68元，较前一交易日下跌1.51%，最新总市值为204.37亿元。该股当日开盘13.88元，最高13.9元，最低13.64元，成交额达1.44亿元，换手率为0.7%。近日，天士力医药集团股份有限公司发布第九届董事会第25次会议决议公告。公告显示，公司于2026年9月24日召开第九届董事会第25次会议，审议通过关于调整公司董事会审计委员会委员的议案。会议应到董事14人，实到14人，表决结果为同意14票，反对0票，弃权0票。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400041300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0188","BK0012","BK0196","BK0239","600535","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669340155","title":"天士力：公司将切实落实“十五五”战略规划中的关键举措","url":"https://stock-news.laohu8.com/highlight/detail?id=2669340155","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669340155?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:36","pubTimestamp":1789976205,"startTime":"0","endTime":"0","summary":"证券之星消息，天士力(600535)09月21日在投资者关系平台上答复投资者关心的问题。投资者提问：公司为什么不能进行回购？股价多少年未涨。现阶段分红的意义远比不上回购注销。天士力回复：感谢您的关注，收到您的建议。公司将切实落实“十五五”战略规划中的关键举措，提升公司的经营质量，加快产品研发创新效率，为公司创造长期价值，同时密切关注市场情况，如有回购等相关安排，公司会按照信息披露相关规定及时进行披露，感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100014193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600535","BK0012","BK0239","BK0183","BK0188","BK0028","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669553711","title":"天士力：公司拥有在研创新药33项","url":"https://stock-news.laohu8.com/highlight/detail?id=2669553711","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669553711?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:36","pubTimestamp":1789976203,"startTime":"0","endTime":"0","summary":"证券之星消息，天士力(600535)09月21日在投资者关系平台上答复投资者关心的问题。投资者提问：公司Ⅲ期临床可有重磅产品？天士力回复：感谢您的关注，根据公司2026年半年报，公司拥有在研创新药33项（上半年神经/精神领域新立项2项），其中处于NDA/Pre NDA阶段3项，处于临床II、III期阶段18项。产品详细信息请参考2026年半年报P17页公司重点创新产品研发进度表，谢谢。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100014190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1161","BK0188","BK0012","BK0028","BK0239","BK0196","BK0183","BK1574","600535","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667617867","title":"研报掘金丨东方证券：维持天士力“买入”评级，核心品种稳健增长，创新管线蓄势待发","url":"https://stock-news.laohu8.com/highlight/detail?id=2667617867","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667617867?lang=zh_cn&edition=full","pubTime":"2026-09-15 15:48","pubTimestamp":1789458484,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0188","600535","BK0183","BK0196","600958","BK0012","BK0239","BK0028","BK0276"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792974148657,"stockEarnings":[{"period":"1week","weight":-0.0185},{"period":"1month","weight":0.0091},{"period":"3month","weight":-0.1107},{"period":"6month","weight":-0.0343},{"period":"1year","weight":-0.1059},{"period":"ytd","weight":-0.0632}],"compareEarnings":[{"period":"1week","weight":-0.0069},{"period":"1month","weight":-0.0625},{"period":"3month","weight":-0.0324},{"period":"6month","weight":-0.0954},{"period":"1year","weight":-0.0591},{"period":"ytd","weight":-0.0701}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"天士力医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"61524人(较上一季度减少2.28%)","perCapita":"24282股","listingDate":"2002-08-23","address":"天津市北辰区普济河东道2号(天士力现代中药城)","registeredCapital":"149395万元","survey":" 天士力医药集团股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是复方丹参滴丸、养血清脑丸（颗粒）、芪参益气滴丸、水林佳（水飞蓟宾胶囊）、注射用重组人尿激酶原（普佑克）、芍麻止痉颗粒。公司连续多年荣获“中国医药工业百强”、“中国医药创新企业100强”、“中国药品研发综合实力50强”、“中国中药研发实力10强”等称号。","listedPrice":14.7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"天士力(600535)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供天士力(600535)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"天士力,600535,天士力股票,天士力股票老虎,天士力股票老虎国际,天士力行情,天士力股票行情,天士力股价,天士力股市,天士力股票价格,天士力股票交易,天士力股票购买,天士力股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"天士力(600535)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供天士力(600535)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}